medigraphic.com
Colegio de Medicina Interna de México.

2009, Number 2

<< Back Next >>

Med Int Mex 2009; 25 (2)

Usefulness of the criteria of the NCEP and IDF metabolic syndrome to identify insulin resistance as assessed by QUICKI

González GJR, Carranza MJ

Language: Spanish
References: 15
Page: 95-100
PDF size: 343.47 Kb.


ABSTRACT

Background: Metabolic syndrome (SM) is public health problem that increases the risk of cardiovascular events (ECV) and diabetes mellitus (DM). There are several clinical approaches to detect SM as indicators from the resistance to the insulin (RI). In our means these approaches have not been contrasted with measurements of RI, for what we ignore its true utility.
Objective: To determine the utility of the clinical approaches of the SM to detect RI using the Quantitative Insulin Sensitivity Check Index (QUICKI).
Method: The patients were detected with SM according to criteria of the NCEP and of the FID, they were calculated the QUICKI = /((log fasting insulin) + (log fasting glucose)). Sensibility (S) was calculated with the formula: S = VP/(VP+FP), the specificity (SP) with the formula: SP = VN/(VN+FN), the positive predictive value: VPP = VP/(VP+VN), the negative predictive value: VPN = FN/(FP+FN), accuracy (A) was calculated by the formula: A = (VP+FN)/(VP+VN+FP+FN). They were considered positive the patients that completed approaches of the SM and positive for the reference test the values of QUICKI ‹ 0.357.
Results: S: 70% NCEP, 69% FID; E: 67% NCEP, 73% FID; VPP: 90% NCEP, 92% FID; VPN: 33% NCEP, 35% FID. Conclusions: Differences don’t exist between the criteria of the NCEP and the FID. The sensibility, and the VPP are superior to the specificity and the VPN. It is necessary to carry out the calculation of the QUICKI, especially when the clinical approaches are negative, since this doesn’t discard that the patients have RI.


REFERENCES

  1. Córdoba JA, Barquera S, Campos I, Hernández M, y col. Análisis de conglomerados de factores de riesgo para enfermedades crónicas en adultos mexicanos. Draft 2007.

  2. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for qualifying insulin secretion and resistance. Am J Physiol 1979:237:214-23.

  3. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79:790-800.

  4. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.

  5. Katz A, Sridhar S, Quon MJ, et al. Quantitative Insulin Sensitivity Check Index: A simple accurate method for assessing insulin sensitivity in humans. Journal of Clin Endocr & Metabol 2000;85(7):2402-10.

  6. Grundi SM, Cleeman JI, Daniela SR, Donato KA, y col. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation published on line Sep 12, 2005.

  7. The IDF (International Diabetes Federation) Consensus Worldwide Definition of the Metabolic Syndrome. April 2005: http // www.idf.org / webdata / docs / Metab_sndrome_def. pdf.

  8. Hrebicek J, Janut V, et al. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. Journal of Clin Endocr & Metabol 2006;87(1):144-47.

  9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATPIII). JAMA 2002;287:356-59.

  10. Sierra-Johnson J, Johnson B, Allison T, Bailey K, et al. Correspondence between the Adult Treatment Panel III criteria for metabolic syndrome and insulin resistance. Diabetes Care 2006;29:668-72.

  11. Cheal K, Abbasi F, Lamendola C, McLaughlin T, et al. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004;53:1195-200.

  12. González O, Arpa A, Herrera D, Álvarez V, González E. Valoración de la insulino resistencia en pacientes con síndrome metabólico. Rev Cub Med Mil 2005;34:1.

  13. McLaughlin T, Abassi F, Cheal K, Chu J, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-9.

  14. Vicario A. Síndrome X. A paradoxically anonymous identity. Medicina 2005;65:154-158.

  15. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDLcholesterol, triglycerides and insulin concentrations. J Intern Med 1992;231:25-30.




2020     |     www.medigraphic.com